N/A N=16 Single-blind Basic Science

The Effects of Immunotherapy in the Nose

Rhinitis, Allergic, Seasonal

Bottom Line

View on ClinicalTrials.gov: NCT01985542 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2021

Primary outcome: Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: birch pollen subcutaneous immunotherapy (Drug)
Age: Pediatric, Adult · 12+ yrs
Sex: All
Sponsor: Helsinki University Central Hospital
Primary completion: Nov 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY The Total Number of Differentially Expressed Transcripts.	119; 49	—
SECONDARY Percentage Change in Visual Analogue Scale Scores of Symptoms	-68; 91	—

Summary

Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and other environmental insults. About 20 % of the European population suffers from pollen allergies. Birch pollen allergic rhinitis is the most common allergic disease in the Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of pollen allergies may be reduced by understanding the molecular biology of the nasal barriers during allergic response. Our aim is to observe the effect of season and birch pollen immunotherapy on the molecular biology of nasal epithelium and the microbiome.

Eligibility Criteria

Inclusion Criteria

allergic rhinoconjunctivitis of birch pollen OR healthy controls

Exclusion Criteria

smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring constant medication

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01985542). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.